VEGF anticorps (C-Term)

N° du produit ABIN6242881

Détail du produit anti-VEGF anticorps

Antigène: VEGF (Vascular Endothelial Growth Factor (VEGF))

Épitope: C-Term

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp VEGF est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Immunogène: This VEGF antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the C-terminal region of human VEGF Antibody.

Clone: RB11705

Isotype: Ig Fraction

Information d'application

Indications d'application: WB: 1:2000. WB: 1:2000. IHC-P: 1:10~50

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Date de péremption: 6 months

Détails sur VEGF

Antigène: VEGF (Vascular Endothelial Growth Factor (VEGF))

Autre désignation: VEGF (VEGF Produits)

Synonymes: anticorps MVCD1, anticorps VEGF, anticorps VPF, anticorps Vegf, anticorps Vegf120, anticorps Vegf164, anticorps Vegf188, anticorps Vpf, anticorps VEGF-A, anticorps VEGF164, anticorps eVEGF120, anticorps eVEGF164, anticorps vegf-a, anticorps vegf, anticorps vascular endothelial growth factor A, anticorps vascular endothelial growth factor A L homeolog, anticorps vascular endothelial growth factor, anticorps vascular endothelial growth factor precursor, anticorps VEGFA, anticorps Vegfa, anticorps vegfa.L, anticorps VEGF, anticorps vegf

Sujet: Embryonic vascular system undergoes a series of complex, highly regulated series of events involving differentiation, migration and association of primitive endothelial cells. This process is termed vasculogenesis. A further remodeling of the primitive vascular system forms the mature cardiovascular system. This process is known as angiogenesis (sprouting of new capillary vessels from pre-existing vasculature). Angiogenesis accounts for the formation of vasculature into previously avascular organs such as brain and kidney. Angiogenic activity in the adult is required during the normal tissue repair, and for the remodeling of the female reproductive organs (ovulation and placental development). Certain pathological conditions, such as tumor growth and diabetic retinopathy, also require angiogenesis. Study of tumor angiogenesis has led to the identification of several proteins including basic fibroblast growth factor (bFGF) and vascular endothelial growth factor. VEGF acts by interacting with a family of largely endothelial-specific receptor tyrosine kinases that includes VEGFR-1 (flt-1), VEGFR-2 (flk-1/KDR), and VEGFR-3/Flt-4. Disruption of VEGFRs interferes with differentiation of endothelial cells and it is lethal for the embryo. VEGF is a heparin-binding glycoprotein that is secreted as a homodimer of 45 kDa.

Poids moléculaire: 27042

NCBI Accession: NP_001020537, NP_001020538, NP_001020539, NP_001020540, NP_001020541, NP_001028928, NP_001165093, NP_001165094, NP_001165095, NP_001165096, NP_001165097, NP_001165098, NP_001165099, NP_00

UniProt: P15692